Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Estudo duplo-cego randomizado controlado por placebo de 24 semanas para avaliar a eficácia, farmacocinética e segurança de LOU064 em adolescentes (12 -

14 de outubro de 2026 atualizado por: Novartis Pharmaceuticals

Um estudo duplo-cego, randomizado e controlado por placebo para avaliar a eficácia, a farmacocinética e a segurança do remibrutinibe (LOU064) por 24 semanas em adolescentes de 12 a menos de 18 anos de idade com urticária crônica espontânea controlada inadequadamente por anti-histamínicos H1 seguidos por uma extensão aberta opcional por até mais 3 anos e um período opcional de acompanhamento sem tratamento de segurança a longo prazo por até 3 anos adicionais

The purpose of this trial is:

  1. to assess the efficacy, pharmacokinetics, and safety of remibrutinib vs. placebo in adolescents from 12 to < 18 years of age suffering from chronic spontaneous urticaria inadequately controlled by H1-antihistamines
  2. to collect long-term efficacy, safety and tolerability data on remibrutinib in adolescents after having completed 24 weeks of treatment
  3. to collect safety data in this population for up to three years after the last dose of study treatment

Visão geral do estudo

Status

Ativo, não recrutando

Descrição detalhada

This trial consists of 3 different periods:

  1. the "core period", which is randomized and double-blind, during which 2/3 participants will receive remibrutinib and 1/3 will receive placebo for 24 weeks. Total duration: approximately 32 weeks (10 site visits).
  2. an optional "open-label extension (OLE) period" proposed to all participants who completed 24 weeks of treatment of the "core period" and all scheduled assessments planned at week 24 visit . Depending on their CSU symptoms (as assessed by the doctor), participants will either receive remibrutinib for 24 weeks, or enter an observational treatment-free period for 1 year. If the CSU symptoms return during the observational period, the participants can switch to the treatment period at any time (decided by the doctor). At the end of the 24-week treatment period, if CSU is controlled, participants will enter the 1-year observational period, otherwise, they can continue with another cycle of 24-week remibrutinib treatment. The number of remibrutinib treatment or observational cycles will be limited to 6 times each. Total duration: from 1 year to approximately 3 years, and number of visits: from 3 to 15 (depending on the CSU symptoms).
  3. an optional "long-term treatment-free follow-up period" proposed to all participants who completed at least 4 months treatment in the "OLE period". No treatment will be given. Duration: 3 years with 1 site visit and up to 4 phone call follow-up visits.

The primary clinical question of interest is what is the effect of remibrutinib treatment versus placebo on the change from baseline in UAS7, ISS7 and HSS7 scores after 12 weeks of treatment

Tipo de estudo

Intervencional

Inscrição (Real)

100

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Berlin, Alemanha, 13353
        • Novartis Investigative Site
      • Tübingen, Alemanha, 72076
        • Novartis Investigative Site
    • Hesse
      • Frankfurt am Main, Hesse, Alemanha, 60590
        • Novartis Investigative Site
      • CABA, Argentina, C1181ACH
        • Novartis Investigative Site
      • San Miguel de Tucumán, Argentina, T4000AXL
        • Novartis Investigative Site
    • Buenos Aires
      • CABA, Buenos Aires, Argentina, C1414AIF
        • Novartis Investigative Site
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentina, S2000DEJ
        • Novartis Investigative Site
    • Quebec
      • Montreal, Quebec, Canadá, H4A 3J1
        • Novartis Investigative Site
    • Santiago Metropolitan
      • Santiago, Santiago Metropolitan, Chile, 8420383
        • Novartis Investigative Site
      • Beijing, China, 100050
        • Novartis Investigative Site
      • Beijing, China, 100069
        • Novartis Investigative Site
    • Guangdong
      • Guangzhou, Guangdong, China, 510091
        • Novartis Investigative Site
    • Sichuan
      • Chengdu, Sichuan, China, 610041
        • Novartis Investigative Site
      • Valencia, Espanha, 46014
        • Novartis Investigative Site
    • Barcelona
      • Esplugues, Barcelona, Espanha, 08950
        • Novartis Investigative Site
    • California
      • Bakersfield, California, Estados Unidos, 93301
        • Kern Research
      • San Diego, California, Estados Unidos, 92123
        • Allergy and Asthma Medical Group and Research Center
    • Florida
      • Miami, Florida, Estados Unidos, 33156
        • Pediatric Dermatology of Miami at the Pediatric CoE
    • Idaho
      • Boise, Idaho, Estados Unidos, 83706
        • Treasure Valley Medical Research
    • Illinois
      • Glenview, Illinois, Estados Unidos, 60077
        • Endeavor Health
    • Kentucky
      • Owensboro, Kentucky, Estados Unidos, 42301
        • Allergy and Asthma Specialist P S C
    • Ohio
      • Toledo, Ohio, Estados Unidos, 43617
        • Toledo Institute of Clinical Research
    • Oklahoma
      • Oklahoma City, Oklahoma, Estados Unidos, 73120
        • Allergy Asthma and Clinical Research
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Estados Unidos, 15241
        • Allergy and Clinical Immunology Associates
    • Texas
      • San Antonio, Texas, Estados Unidos, 78213
        • RFSA Dermatology
    • Utah
      • Sandy City, Utah, Estados Unidos, 84093
        • Allergy Associates of Utah
      • Utrecht, Holanda, 3584 CX
        • Novartis Investigative Site
    • Hong Kong
      • Hong Kong, Hong Kong, Hong Kong, 999077
        • Novartis Investigative Site
    • FI
      • Florence, FI, Itália, 50139
        • Novartis Investigative Site
    • PV
      • Pavia, PV, Itália, 27100
        • Novartis Investigative Site
    • SI
      • Siena, SI, Itália, 53100
        • Novartis Investigative Site
    • Fukuoka
      • Kitakyushu, Fukuoka, Japão, 8078556
        • Novartis Investigative Site
    • Kumamoto
      • Kamimashi-gun, Kumamoto, Japão, 8613106
        • Novartis Investigative Site
    • Osaka
      • Sakai, Osaka, Japão, 5938324
        • Novartis Investigative Site
    • Shimane
      • Izumo, Shimane, Japão, 6938501
        • Novartis Investigative Site
    • Tokyo
      • tabashi City, Tokyo, Japão, 1738610
        • Novartis Investigative Site
    • Sarawak
      • Kuching, Sarawak, Malásia, 93586
        • Novartis Investigative Site
      • Lodz, Polônia, 90-436
        • Novartis Investigative Site
      • Manchester, Reino Unido, M13 9WL
        • Novartis Investigative Site
      • Southampton, Reino Unido, SO16 6YD
        • Novartis Investigative Site
    • Cambridgeshire
      • Peterborough, Cambridgeshire, Reino Unido, PE3 9GZ
        • Novartis Investigative Site
      • Bangkok, Tailândia, 10330
        • Novartis Investigative Site
      • Bangkok, Tailândia, 10700
        • Novartis Investigative Site
    • Hat Yai
      • Songkhla, Hat Yai, Tailândia, 90110
        • Novartis Investigative Site
      • Adana, Turquia (Türkiye), 01330
        • Novartis Investigative Site
    • Fatih
      • Istanbul, Fatih, Turquia (Türkiye), 34093
        • Novartis Investigative Site
    • Sihhiye Altindag
      • Ankara, Sihhiye Altindag, Turquia (Türkiye), 06230
        • Novartis Investigative Site
      • Cape Town, África do Sul, 7925
        • Novartis Investigative Site
    • Gauteng
      • Pretoria, Gauteng, África do Sul, 0181
        • Novartis Investigative Site

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

12 anos a 17 anos (Filho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Key Inclusion Criteria:

  • Male and female adolescent participants aged >= 12 to < 18 years of age at the time of signing the informed consent
  • CSU duration for >= 6 months prior to screening (defined as the onset of CSU determined by the investigator based on all available supporting documentation)
  • Diagnosis of CSU inadequately controlled by second-generation H1-AH at the time of randomization defined as:
  • The presence of itch and hives for ≥ 6 consecutive weeks prior to screening despite the use of second-generation H1-AH during this time period according to local treatment guidelines
  • UAS7 score (range 0 - 42) >= 16, ISS7 score (range 0 - 21) >= 6 and HSS7 score (range 0 - 21) >= 6 during the 7 days prior to randomization (Day 1)
  • Documentation of hives within three months before randomization (either at screening and/or at randomization; or documented in the participants' medical history)

Key Exclusion criteria:

  • Previous use of remibrutinib or other BTK inhibitors
  • Significant bleeding risk or coagulation disorders
  • History of gastrointestinal bleeding
  • Requirement for anti-platelet medication, except for acetylsalicylic acid up to 100 mg/d or clopidogrel up to 75 mg/d. The use of dual anti-platelet therapy (e.g., acetylsalicylic acid + clopidogrel) is prohibited
  • History or current hepatic disease
  • Evidence of clinically significant cardiovascular, neurological, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, hematological disorders, gastrointestinal disease or immunodeficiency that, in the investigator's opinion, would compromise the safety of the participant, interfere with the interpretation of the study results or otherwise preclude participation or protocol adherence of the participant
  • History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar chemical classes
  • Participants having a clearly defined predominant or sole trigger of their chronic urticaria (chronic inducible urticaria) including urticaria factitia (symptomatic dermographism), cold-, heat-, solar-, pressure-, delayed pressure-, aquagenic-, cholinergic-, or contact-urticaria
  • Other diseases with symptoms of urticaria or angioedema, including but not limited to urticaria vasculitis, urticaria pigmentosa, erythema multiforme, mastocytosis, hereditary angioedema, or drug-induced urticaria
  • Any other skin disease associated with chronic itching that might influence in the investigator's opinion the study evaluations and results, e.g., atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus or psoriasis

Other protocol-defined inclusion/exclusion criteria may apply.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Arm 1: LOU064 (blinded)

LOU064 (blinded) taken orally b.i.d. for 24 weeks, followed by LOU064 (open-label) taken orally b.i.d. for up to 6 cycles of 24 weeks.

LOU064 (blinded) active treatment

Outros nomes:
  • remibrutinibe
Comparador de Placebo: Arm 2: LOU064 placebo (blinded)

LOU064 placebo (blinded) taken orally b.i.d. for 24 weeks (randomized in a 2:1 ratio arm 1: arm 2)

matching active drug

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change from baseline in UAS7
Prazo: Baseline, week 12

The Urticaria Activity Score (UAS) is sum of the Hive Severity Score (HSS) and the Itch Severity Score (ISS). UAS7 is sum of the HSS7 and the ISS7 scores. Possible range of weekly UAS7 score is 0 to 42. Complete UAS7 response is UAS7 = 0.

Negative change from baseline indicates improvement.

Baseline, week 12
Change fron baseline in ISS7
Prazo: Baseline, Week 12

Itch Severity Score (ISS) scale is 0 to 3. Score (ISS7) is derived by adding up average daily scores of 7 days preceding visit. Possible range of weekly score is therefore 0 to 21. Itch Severity Score scale: 0 - None 1 - Mild (minimal awareness, easily tolerated) 2 - Moderate (definite awareness, bothersome but tolerable) 3 - Severe (difficult to tolerate).

Negative change from baseline indicates improvement.

Baseline, Week 12
Change from baseline in HSS7
Prazo: Baseline, Week 12

Hives Severity Score (HSS) scale is 0 to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. Possible range of the weekly score is therefore 0 to 21. Hives Severity Score scale: 0 - None 1 - Mild (1-6 hives/12 hours) 2 - Moderate (7-12 hives/12 hours) 3 - Severe (>12 hives/12 hours).

Negative change from baseline indicates improvement.

Baseline, Week 12

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Cmax of remibrutinib
Prazo: At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake

The maximum (peak) observed blood drug concentration after single dose administration

At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake
Tmax of remibrutinib
Prazo: At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake

The time to reach maximum (peak) blood drug concentration after single dose administration

At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake
AUClast of remibrutinib
Prazo: At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake

The Area Under the Curve (AUC) from pre-dose to the last measurable concentration sampling time

At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake
Absolute change from baseline in ISS7
Prazo: Baseline - Week 12

Itch Severity Score (ISS) scale is 0 to 3. Score (ISS7) is derived by adding up average daily scores of 7 days preceding visit. Possible range of weekly score is therefore 0 to 21. Itch Severity Score scale: 0 - None 1 - Mild (minimal awareness, easily tolerated) 2 - Moderate (definite awareness, bothersome but tolerable) 3 - Severe (difficult to tolerate).

Negative change from baseline indicates improvement.

Baseline - Week 12
Absolute change from baseline in HSS7
Prazo: Baseline - Week 12

Hives Severity Score (HSS) scale is 0 to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. Possible range of the weekly score is therefore 0 to 21. Hives Severity Score scale: 0 - None 1 - Mild (1-6 hives/12 hours) 2 - Moderate (7-12 hives/12 hours) 3 - Severe (>12 hives/12 hours).

Negative change from baseline indicates improvement.

Baseline - Week 12
Achievement of UAS7 ≤ 6 (yes/no)
Prazo: Week 12 and over time

Disease activity control is defined as UAS7 ≤ 6. The Urticaria Activity Score (UAS) is sum of the Hive Severity Score (HSS) and the Itch Severity Score (ISS). UAS7 is sum of the HSS7 and the ISS7 scores. Possible range of weekly UAS7 score is 0 to 42.

Week 12 and over time
Achievement of UAS7 = 0 (yes/no)
Prazo: Week 12 and over time

Complete absence of hives and itch is defined as UAS7 = 0. The Urticaria Activity Score (UAS) is sum of the Hive Severity Score (HSS) and the Itch Severity Score (ISS). UAS7 is sum of the HSS7 and the ISS7 scores. Possible range of weekly UAS7 score is 0 to 42.

Week 12 and over time
Absolute change from baseline in CDLQI score
Prazo: Week 12

The Children Dermatology life Quality Index (CDLQI) score range is 0 to 30, with 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life).

Week 12
Number of weeks without angioedema, assessed by the cumulative number of weeks with an AAS7 = 0 response
Prazo: baseline - Week 12

Angioedema Activity Score (AAS7) is a measure of the frequency and intensity of angioedema episodes. The total possible range of scores over 7 days is 0-105 where higher scores indicate increased angioedema activity.

baseline - Week 12
Occurrence of treatment-emergent adverse events (AE) and serious adverse events (SAE) during the core period
Prazo: 28 weeks

To demonstrate the safety and tolerability of remibrutinib by assessing occurrence of treatment emergent adverse events and serious adverse events during the core period of the study.

28 weeks
Occurrence of treatment emergent AEs, and SAEs during the Open Label Extension (OLE) period
Prazo: 3 years

To demonstrate the safety and tolerability of remibrutinib by assessing occurrence of treatment emergent adverse events and serious adverse events during the OLE period of the study.

3 years

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Diretor de estudo: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

11 de julho de 2023

Conclusão Primária (Estimado)

3 de novembro de 2026

Conclusão do estudo (Estimado)

30 de março de 2032

Datas de inscrição no estudo

Enviado pela primeira vez

16 de dezembro de 2022

Enviado pela primeira vez que atendeu aos critérios de CQ

23 de dezembro de 2022

Primeira postagem (Real)

10 de janeiro de 2023

Atualizações de registro de estudo

Última Atualização Postada (Real)

15 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

14 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever